StreetInsider.com News Articles

Haemonetics (HAE) PT Raised to $86 at JPMorgan

Fri, 07 Aug 2026 09:03:27 -0400

JPMorgan analyst Allen Gong raised the price target on Haemonetics (NYSE: HAE) to $86.00 (from $62.00) while maintaining a Neutral rating.

Form S-8 HAEMONETICS CORP

Thu, 06 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260806/26884359.html

Form S-8 HAEMONETICS CORP

Thu, 06 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260806/26884359.html

Haemonetics (HAE) PT Raised to $96 at BTIG

Thu, 06 Aug 2026 13:22:09 -0400

(Updated - August 6, 2026 1:22 PM EDT)

BTIG analyst Marie Thibault raised the price target on Haemonetics (NYSE: HAE) to $96.00 (from $84.00) while maintaining a Buy rating.

The analyst commented: "Haemonetics reported F1Q revenue of $339.4M (+5.6% y/y rep., +5.9% y/y org. ex-CSL), beating consensus of $327.9M. Adj. EPS of $1.14 was six cents better than consensus. All segments exceeded estimates: Apheresis sales of $191.3M (Visible Alpha cons. $180.6M), with Plasma of $155.5M (VA cons. $146.0M) as the primary driver; and a beat in MedSurg as well with Interventional Technologies of $59.9M (VA cons. $59.0M) and Blood Management Technologies of

Haemonetics (HAE) PT Raised to $96 at BTIG

Thu, 06 Aug 2026 13:22:09 -0400

(Updated - August 6, 2026 1:22 PM EDT)

BTIG analyst Marie Thibault raised the price target on Haemonetics (NYSE: HAE) to $96.00 (from $84.00) while maintaining a Buy rating.

Haemonetics (HAE) Tops Q1 EPS by 5c, Beats on Revenue

Thu, 06 Aug 2026 06:13:32 -0400

Haemonetics (NYSE: HAE) reported Q1 EPS of $1.14, $0.05 better than the analyst estimate of $1.09. Revenue for the quarter came in at $339 million versus the consensus estimate of $328.92 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

Form 10-Q HAEMONETICS CORP For: Jun 27

Thu, 06 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26877662.html

Form 10-Q HAEMONETICS CORP For: Jun 27

Thu, 06 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26877662.html

Form 8-K HAEMONETICS CORP For: Aug 06

Thu, 06 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26877650.html

Form 8-K HAEMONETICS CORP For: Aug 06

Thu, 06 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26877650.html

Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website

Thu, 06 Aug 2026 06:00:00 -0400

Financial release and supplemental presentation accessible online

BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2027, which ended June 27, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 6, 2026.

Conference Call and Webcast Information:

Registration: Click here to register. Upon registration, participants will receive

Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website

Thu, 06 Aug 2026 06:00:00 -0400

Financial release and supplemental presentation accessible online

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 6, 2026.

Conference Call and Webcast Information:

Registration: Click here to register. Upon registration, participants will receive

Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website

Thu, 06 Aug 2026 06:00:00 -0400

Financial release and supplemental presentation accessible online

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 6, 2026.

Conference Call and Webcast Information:

Registration: Click here to register. Upon registration, participants will receive

Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website

Thu, 06 Aug 2026 06:00:00 -0400

Financial release and supplemental presentation accessible online

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 6, 2026.

Conference Call and Webcast Information:

Registration: Click here to register. Upon registration, participants will receive

Haemonetics study backs vascular closure device in large-bore procedures

Mon, 03 Aug 2026 16:16:37 -0400

Haemonetics Corporation (NYSE: HAE) announced the publication of a retrospective cohort study evaluating outcomes of its VASCADE MVP XL venous vascular closure system in large-bore sheath electrophysiology procedures, according to a company press release dated Aug. 3, 2026.

The study, conducted at Emory University and funded by a grant from Haemonetics, included 1,623 patients who underwent procedures using sheaths up to 17F outer diameter, including pulsed field ablation for atrial fibrillation, left atrial appendage closure, and concomitant procedures. The company described it as the largest reported cohort using the VASCADE MVP XL system to date.

Results showed a median hemostasis time of

Haemonetics study backs vascular closure device in large-bore procedures

Mon, 03 Aug 2026 16:16:37 -0400

Results showed a median hemostasis time of

New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths